Addressing unmet clinical needs with targeted therapeutic radiopharmaceuticals
PIPELINE
Blue Earth Therapeutics is committed to the advancement of next generation targeted radiotherapeutics to transform the clinical management of patients with cancer in areas of unmet clinical need.
Blue Earth Therapeutics has acquired exclusive, worldwide rights to radiohybrid Prostate-Specific Membrane Antigen (rhPSMA)-targeted technology, and has a research programme initially focused on prostate cancer.
OUR PIPELINE
Blue Earth Therapeutics is investigating the use of the rhPSMA molecule for therapy with the addition of an alpha or beta emitting radioisotope.
|
PRODUCT/CANDIDATE
|
POTENTIAL USE
|
APPLICATION
|
PRECLINICAL
|
PHASE 1
|
PHASE 2
|
PHASE 3
|
APPROVED (US)
|
APPROVED (EU)
|
|
177Lu-rhPSMA-10.1 |
Prostate Cancer |
Radiopharmaceutical Therapy |
|
|||||
|
225Ac-rhPSMA-10.1 |
Prostate Cancer |
Radiopharmaceutical Therapy |
|
Our sister company, Blue Earth Diagnostics, continues to investigate the use of 18F-rhPSMA-7.3 as a diagnostic imaging agent for prostate cancer, in addition to exploring other promising imaging agents (see more at https://www.blueearthdiagnostics.com/pipeline/ ).
PP-UK-0458/February 2022
